Next Article in Journal
Near Infrared Fluorescence Imaging of Intraperitoneal Ovarian Tumors in Mice Using Erythrocyte-Derived Optical Nanoparticles and Spatially-Modulated Illumination
Previous Article in Journal
Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
Review

Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

1
Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
2
Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA
3
Medical Scientist Training Program, University of Illinois College of Medicine, Chicago, IL 60612, USA
4
Jesse Brown VA Medical Center, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Michelino De Laurentiis
Cancers 2021, 13(11), 2543; https://doi.org/10.3390/cancers13112543
Received: 30 March 2021 / Revised: 18 May 2021 / Accepted: 20 May 2021 / Published: 22 May 2021
Despite recent advances in the treatment of other breast cancer subtypes, inflammatory breast cancer (IBC) remains a significant clinical challenge, with an overall 5-year survival rate of 39%. Though immunotherapy has shown remarkable efficacy in other difficult-to-treat cancers, such approaches have yet to show substantial therapeutic efficacy in IBC. Here, we summarize the known immune composition of IBC tumors, as well as past and present efforts to advance immunotherapy in the treatment of IBC.
Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. Despite the efficacy of immunotherapy in other difficult to treat forms of breast cancer, progress for immunotherapy in IBC has been difficult. Though immunotherapy has been under clinical investigation in IBC since the 1970s, few approaches have shown significant therapeutic efficacy, and no immunotherapy regimens are currently used in the treatment of IBC. Here, we provide a comprehensive summary of what is known about the immune composition of IBC tumors, clinical and basic science evidence describing the role for immune checkpoints such as PD-L1 in IBC pathobiology, as well as past and present attempts to advance ICIs in the treatment of IBC. View Full-Text
Keywords: inflammatory breast cancer; immunotherapy; immune checkpoint inhibitors; tumor microenvironment; tumor immunology inflammatory breast cancer; immunotherapy; immune checkpoint inhibitors; tumor microenvironment; tumor immunology
Show Figures

Figure 1

MDPI and ACS Style

Koch, R.M.; Principe, D.R.; Cataneo, J.L.; Rana, A. Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers 2021, 13, 2543. https://doi.org/10.3390/cancers13112543

AMA Style

Koch RM, Principe DR, Cataneo JL, Rana A. Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers. 2021; 13(11):2543. https://doi.org/10.3390/cancers13112543

Chicago/Turabian Style

Koch, Regina M., Daniel R. Principe, Jose L. Cataneo, and Ajay Rana. 2021. "Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy" Cancers 13, no. 11: 2543. https://doi.org/10.3390/cancers13112543

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop